Vilarem M[au] - Search Results

Year	Number of Results
1973	1
1975	1
1978	1
1981	1
1982	1
1984	3
1985	1
1986	3
1987	2
1988	2
1990	1
1992	3
1994	1
1997	2
1998	2
1999	1
2000	3
2001	3
2002	2
2003	6
2004	2
2005	3
2006	4
2007	6
2008	4
2009	2
2010	1
2022	0

1

Pathophysiological factors affecting CAR gene expression.

Pascussi JM, Dvorák Z, Gerbal-Chaloin S, Assenat E, Maurel P, Vilarem MJ. Pascussi JM, et al. Among authors: vilarem mj. Drug Metab Rev. 2003 Nov;35(4):255-68. doi: 10.1081/dmr-120026394. Drug Metab Rev. 2003. PMID: 14705859 Review.

2

[[Inflammation and drug metabolism: NF-kappB and the CAR and PXR xeno-receptors].

Pascussi JM, Vilarem MJ. Pascussi JM, et al. Among authors: vilarem mj. Med Sci (Paris). 2008 Mar;24(3):301-5. doi: 10.1051/medsci/2008243301. Med Sci (Paris). 2008. PMID: 18334180 Free article. Review. French.

3

The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences.

Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. Pascussi JM, et al. Among authors: vilarem mj. Annu Rev Pharmacol Toxicol. 2008;48:1-32. doi: 10.1146/annurev.pharmtox.47.120505.105349. Annu Rev Pharmacol Toxicol. 2008. PMID: 17608617 Review.

4

Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response.

Moreau A, Vilarem MJ, Maurel P, Pascussi JM. Moreau A, et al. Among authors: vilarem mj. Mol Pharm. 2008 Jan-Feb;5(1):35-41. doi: 10.1021/mp700103m. Epub 2007 Dec 27. Mol Pharm. 2008. PMID: 18159929 Review.

5

Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences.

Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assénat E, Larrey D, Pichard-Garcia L, Vilarem MJ, Maurel P. Pascussi JM, et al. Among authors: vilarem mj. Xenobiotica. 2004 Jul;34(7):633-64. doi: 10.1080/00498250412331285454. Xenobiotica. 2004. PMID: 15672753 Review.

6

The in vitro involvement of topoisomerase II in the activity of aza-ellipticine analogues is not correlated with drug activity on isolated nuclei.

Vilarem MJ, Riou JF, Multon E, Gras MP, Larsen CJ. Vilarem MJ, et al. Biochem Pharmacol. 1986 Jul 1;35(13):2087-95. doi: 10.1016/0006-2952(86)90575-7. Biochem Pharmacol. 1986. PMID: 3015146

7

Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?

Assenat E, Gerbal-chaloin S, Maurel P, Vilarem MJ, Pascussi JM. Assenat E, et al. Among authors: vilarem mj. Eur J Cancer. 2006 Apr;42(6):785-92. doi: 10.1016/j.ejca.2006.01.005. Epub 2006 Feb 28. Eur J Cancer. 2006. PMID: 16510279 Review.

8

The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors.

Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. Pascussi JM, et al. Among authors: vilarem mj. Biochim Biophys Acta. 2003 Feb 17;1619(3):243-53. doi: 10.1016/s0304-4165(02)00483-x. Biochim Biophys Acta. 2003. PMID: 12573484 Review.

9

Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3).

Breuker C, Moreau A, Lakhal L, Tamasi V, Parmentier Y, Meyer U, Maurel P, Lumbroso S, Vilarem MJ, Pascussi JM. Breuker C, et al. Among authors: vilarem mj. Endocrinology. 2010 Apr;151(4):1653-61. doi: 10.1210/en.2009-1435. Epub 2010 Feb 25. Endocrinology. 2010. PMID: 20185760

10

Identification of proteomic changes during human liver development by 2D-DIGE and mass spectrometry.

Brizard JP, Ramos J, Robert A, Lafitte D, Bigi N, Sarda P, Laoudj-Chenivesse D, Navarro F, Blanc P, Assenat E, Maurel P, Pascussi JM, Vilarem MJ. Brizard JP, et al. Among authors: vilarem mj. J Hepatol. 2009 Jul;51(1):114-26. doi: 10.1016/j.jhep.2009.02.029. Epub 2009 Apr 17. J Hepatol. 2009. PMID: 19443070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results